Cargando…

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors

Hodgkin lymphoma (HL) is a hematopoietic malignancy of B-cells that has a bimodal distribution with respect to age and incidence. With the introduction of doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) and radiation combined, the prognosis of HL has significantly improved,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schimmoeller, Christopher J, Bastian, Craig, Fleming, Jessica, Morales, Joshua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411984/ https://www.ncbi.nlm.nih.gov/pubmed/37565112 http://dx.doi.org/10.7759/cureus.41660

Ejemplares similares

Yescarta: A New Era for Non-Hodgkin Lymphoma Patients
por: AlDallal, Salma M
Publicado: (2020)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
por: Jennane, Selim, et al.
Publicado: (2022)

The role of transplantation in Hodgkin lymphoma
por: Maranzano, Michael, et al.
Publicado: (2023)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
por: Renner, Christoph, et al.
Publicado: (2018)

Advances in Hodgkin Lymphoma: Including the Patient’s Voice
por: Smith, Christine Moore, et al.
Publicado: (2022)

The Impact of Protocol Assignment for Older Adolescents with Hodgkin Lymphoma
por: Pieters, Richard S., et al.
Publicado: (2014)

Genetically Determined Height and Risk of Non-hodgkin Lymphoma
por: Moore, Amy, et al.
Publicado: (2020)

Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma
por: Berkowitz, Callie, et al.
Publicado: (2022)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

Non-Hodgkin’s Lymphoma: An Unusual Cause of Shoulder Pain
por: Yeak, Raymond D.K., et al.
Publicado: (2023)

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma
por: Lv, Liwei, et al.
Publicado: (2021)

Clinical and Epidemiological Profile of Elderly Hodgkin’s Lymphoma in India
por: Sharma, Manish, et al.
Publicado: (2022)

Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma
por: Gaudel, Pramod, et al.
Publicado: (2022)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Optic Neuritis: A Rare Paraneoplastic Phenomenon of Hodgkin's Lymphoma
por: Khan, Yasir, et al.
Publicado: (2019)

Non-Hodgkin’s Lymphoma Presenting as Isolated Peritoneal Lymphomatosis: A Case Report and Literature Review
por: Zhu, Min, et al.
Publicado: (2021)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin’s Lymphoma Cells
por: Kewitz, Stefanie, et al.
Publicado: (2013)

Retroperitoneal extra-adrenal non-Hodgkin lymphoma: An uncommon presentation
por: Ayari, Y., et al.
Publicado: (2018)

Modeling Gene-Environment Interaction for the Risk of Non-hodgkin Lymphoma
por: Zhang, Jiahui, et al.
Publicado: (2019)

Advanced Hodgkin Lymphoma: a New Era of Therapy
por: Dann, Eldad J.
Publicado: (2014)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Classical Hodgkin Lymphoma on the Background of Castleman Disease: A Case Report
por: Ma'koseh, Mohammad, et al.
Publicado: (2023)

Radiotherapy for Non-Hodgkin’s lymphoma with cardiac infiltration: A case report
por: Wang, Weifeng, et al.
Publicado: (2023)

Hodgkin Lymphoma Monozygotic Triplets Reveal Divergences in DNA Methylation Signatures
por: Xia, Chuanyou, et al.
Publicado: (2020)

The prognostic value of Epstein−Barr virus infection in Hodgkin lymphoma: A systematic review and meta-analysis
por: Hu, Jianyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kv6gmnd1nt2g9fuorcshs54bf4